Gossamer Bio, Inc.
seralutinib
pulmonary arterial hypertension
Resolved
134days ago
Phase 3 readout · Feb 23, 2026
What's at stake
Phase 3 trial results for seralutinib in pulmonary arterial hypertension are due Feb 23, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“On February 23, 2026, Gossamer Bio, Inc. (the “Company” or “Gossamer”) announced topline results from its Phase 3 PROSERA study of seralutinib in patients with pulmonary arterial hypertension (PAH).”